Previous 10 | Next 10 |
Valneva ( NASDAQ: VALN ) ( OTCPK:INRLF ) said it completed enrollment and vaccination for a phase 3 trial of its single-shot chikungunya vaccine VLA1553 in adolescents. First results of the trial, dubbed VLA1553-321, are expected mid-2023. The trial was conduct...
Valneva ( NASDAQ: VALN ) ( OTCPK:INRLF ) said it completed a rolling submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of its single-shot chikungunya vaccine VLA1553 in people aged 18 years and above. The Biologics License Applic...
Shares of France-based biotech Valneva SE ( NASDAQ: VALN ) trended lower in European trading after France's public health body Haute Autorité de santé (HAS) advised against the use of the company's COVID-19 vaccine as part of a broader immunization drive. However, the HAS re...
Valneva SE (VALN) Q3 2022 Earnings Conference Call November 10, 2022 9:00 AM ET Company Participants Thomas Lingelbach – President and Chief Executive Officer Peter Buhler – Chief Financial Officer Conference Call Participants Maury Raycroft...
The following slide deck was published by Valneva SE in conjunction with their 2022 Q3 earnings call. For further details see: Valneva SE 2022 Q3 - Results - Earnings Call Presentation
Valneva press release ( NASDAQ: VALN ): Q3 Cash and cash equivalents of €261.0M at the end of September 2022 Revenue of €249.9M (+258.0% Y/Y). Valneva reiterates expected total revenues of €340 million to €360 million. Product sales...
Valneva ( NASDAQ: VALN ) ( OTCPK:INRLF ) upsized an offering to raise ~€102.9M (~$99.9M) from the previously expected $40M due to excess demand. The French vaccine maker is pricing of 21M ordinary shares in a global offering to certain inve...
Valneva SE ( NASDAQ: VALN ) to issue and sell ~$40M of its ordinary shares in a global offering. Offering is comprised of (i) a public offering of its ADSs, each representing two ordinary shares, in the US and (ii) a concurrent private placement of its shares in ...
French biotech Valneva SE ( NASDAQ: VALN ) announced Monday that the company is in discussions with a partner to secure funding to develop a second-generation COVID-19 vaccine. Previously, the biotech had said it would invest further in the second-generation vaccine if fun...
French biotech Valneva ( NASDAQ: VALN ) on Friday said it had agreed to terminate its COVID-19 vaccine drug substance manufacturing agreement with contract development organization IDT Biologika following the suspension of the manufacturing of the shot. The European Commissi...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 09:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-24 20:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...